Signal changes in T2-weighted MRI of liver metastases under bevacizumab-A practical imaging biomarker?

Johannes ThueringChristiane Katharina KuhlAlexandra BarabaschLea HitpassMaike BodeNina BüntingPhilipp BrunersNils Andreas Krämer

Published in: PloS one (2020)

Liver metastases exhibit considerably hypointense in T2-weighted imaging after treatment with bevacizumab, in contrast to conventionally treated liver metastases. Therefore, T2-weighted imaging seems to reflect the effect of bevacizumab.

Keyphrases

liver metastases
contrast enhanced
magnetic resonance
high resolution
magnetic resonance imaging
network analysis
computed tomography